Airwave Oscillometry – Fast and Easy Assessment of Small Airway Function
Join us for an upcoming webinar, ‘Airwave Oscillometry for faster small airway impairment detection’ on Thursday June 17, 2021 at 8 am PT, 11 am ET, 5 pm CEST, featuring an informal conversation between two industry leaders taking a deeper look into the theory and usage of Oscillometry.
Phil Lake, PhD, Director, Respiratory Solutions at ERT, and Lennart Lunblad, PhD, Director Clinical Science, Thorasys Thoracic Medical Systems Inc will discuss the uses of oscillometry in clinical trials and the potential for oscillometry based endpoints to augment or replace traditional lung function endpoints within clinical trials to better understand the impact of new medicines.
- Share general AOS overview, techniques and measurement
- Interpreting small lung changes and linking to clinical outcomes
- Understanding endpoints to drive label claims for new medicines
- Using AOS to measure lung safety and disease progression in non-respiratory clinical trials.
- Audience Q&A
Phil Lake, PhD
Sr Director, Respiratory Solutions at ERT
Phil Lake, PhD is a respiratory specialist at ERT who supports clients all around the world. Phil has held a variety of roles in drug development for nearly 20 years, predominantly focused on respiratory trials.
Prior to ERT, Phil held positions at SmithKline Beecham and GlaxoSmithKline. There, he worked on a number of anti-inflammatory agents, dual and triple combination therapy, monoclonal antibody studies, anti-infectives and some of the largest mechanistic studies looking at biomarkers within sputum and biopsy samples. He also has experience supporting a number of CROs as a respiratory specialist and as the head of project management. For the last 10 years, he has concentrated extensively on rare respiratory diseases, including Cystic Fibrosis and Idiopathic Pulmonary Fibrosis, covering a variety of drug mechanisms and medical devices. Phil was pivotal to some of the first centralised over read studies and is committed to driving improvements in lung function testing.
He completed his training at University College Cardiff and Southampton University.
Lennart Lunblad, PhD
Director Clinical Science, Thorasys Thoracic Medical Systems Inc
Dr. Lennart Lundblad PhD is the Director for Clinical Sciences at THORASYS Thoracic Medical Systems Inc. and an adjunct Associate Professor at the Meakins-Christie Laboratories at the McGill University in Montréal, Canada.
Dr. Lundblad started working at the University of Vermont (UVM), the Vermont Lung Center in 2001, and directed the VLC Phenotyping Core from 2007 – 2018. He has an extensive network of collaborators and is a valued teacher and mentor to medical students, postgraduates and fellows. He serves on the Pulmonary Research Group Board of Directors and is also their Proceedings Editor. He is a member of the American Physiological Society and the American Thoracic Society and has served on the Conference Planning Committee for the Respiratory Structure and Function Assembly. Before joining UVM Dr. Lundblad worked as a preclinical Research Scientist and Project Leader at AstraZeneca at the Lund facility in Sweden.
As the Director for Clinical Science at Thorasys Inc. Dr. Lundblad continues his work as a scientist in collaboration with internal and external partners, liaising with clients, facilitating and co-authoring articles, designing and administrating research projects, working with corporate clinical and marketing strategies, arranging meetings and workshops, and regulatory documentation.